Sleep Apnea Symptoms: What Could Be Causing Them and What to Do Next

What Sleep Apnea Symptoms Actually Look Like

The hallmark symptoms of sleep apnea go well beyond snoring. Patients typically report a combination of nocturnal breathing pauses witnessed by a bed partner, choking or gasping arousals, nocturia, morning headaches, unrefreshing sleep, and daytime hypersomnolence that impairs concentration and driving safety. The American Academy of Sleep Medicine (AASM) diagnostic criteria require either 15 or more obstructive respiratory events per hour on polysomnography, or 5 or more events per hour combined with at least one clinical symptom such as excessive sleepiness, witnessed apneas, or gasping.

Symptom presentation differs by sex. Women more often report insomnia, fatigue, and mood disturbance rather than loud snoring, which contributes to diagnostic delays averaging 5 years longer than in men [1]. The Wisconsin Sleep Cohort Study, tracking 1,522 state employees over two decades, found that 93% of women and 82% of men with moderate-to-severe sleep-disordered breathing had not received a diagnosis at baseline [2]. These numbers explain why the condition remains one of the most underrecognized contributors to cardiometabolic disease.

Children present differently still. Mouth breathing, behavioral problems resembling ADHD, enuresis, and failure to thrive can all signal pediatric OSA, which the American Academy of Pediatrics estimates affects 1-5% of children [3].

Obstructive Sleep Apnea: The Most Common Cause

Obstructive sleep apnea (OSA) causes 84% of sleep apnea diagnoses and results from repetitive pharyngeal collapse during sleep. The mechanism is straightforward: negative inspiratory pressure generated by the diaphragm exceeds the dilating force of upper airway muscles, and the airway narrows or seals shut. Each obstruction triggers a cortical arousal, fragmenting sleep architecture.

Several anatomical and physiological factors predispose a person to this collapse. A narrow retroglossal airway, enlarged tonsils or adenoids (Mallampati class III-IV), retrognathia, and macroglossia all reduce the baseline pharyngeal lumen. The Endocrine Society's 2017 clinical practice guideline on the endocrine management of obstructive sleep apnea explicitly identifies hypothyroidism and acromegaly as hormonal contributors to upper airway narrowing through soft tissue changes.

Neuromuscular tone matters as much as structure. During REM sleep, genioglossus muscle activity drops to its lowest point, which is why REM-predominant OSA exists as a distinct phenotype. Alcohol consumption within 3 hours of bedtime worsens this relaxation measurably. A crossover trial published in the American Journal of Respiratory and Critical Care Medicine found that moderate alcohol intake increased the AHI by an average of 32.4% in participants with existing mild OSA [4].

How Obesity Drives the Majority of Adult Cases

Excess adiposity is the single strongest modifiable risk factor for OSA. Fat deposition in the parapharyngeal fat pads, tongue base, and lateral pharyngeal walls directly compromises airway patency. The Sleep Heart Health Study (N=6,132) demonstrated that a 10% weight gain predicted a 32% increase in AHI and a six-fold increase in the odds of developing moderate-to-severe sleep-disordered breathing over a 5-year follow-up period [5].

The relationship runs in both directions. OSA itself promotes weight gain through sleep fragmentation, leptin resistance, and reduced physical activity from daytime fatigue. This bidirectional cycle is why the AASM's clinical practice guideline on OSA lists weight management as a first-tier behavioral intervention alongside positional therapy.

Dr. Sanjay Patel, a sleep medicine physician at the University of Pittsburgh, has noted: "The relationship between obesity and obstructive sleep apnea is not merely correlational. Visceral and upper-body fat deposition mechanically loads the airway in ways that no amount of CPAP can permanently fix without addressing the weight itself" [6]. This explains the growing interest in GLP-1 receptor agonists as adjunctive OSA therapy. The SURMOUNT-OSA trial (N=469), published in the New England Journal of Medicine in 2024, found that tirzepatide 10-15 mg reduced AHI by 27.4 events per hour compared to 4.8 with placebo at 52 weeks, alongside 18.1% mean body weight reduction [7].

Central Sleep Apnea: When the Brain Stops Sending the Signal

Central sleep apnea (CSA) accounts for roughly 5-10% of sleep apnea diagnoses and involves a fundamentally different mechanism. The airway does not collapse. Instead, the brainstem's respiratory control centers fail to generate adequate ventilatory drive, producing pauses without thoracoabdominal effort.

The most clinically relevant form is Cheyne-Stokes respiration (CSR) associated with heart failure. In the SERVE-HF trial (N=1,325), published in the New England Journal of Medicine, 50-75% of patients with heart failure and reduced ejection fraction (HFrEF) exhibited CSA on polysomnography [8]. CSR creates a characteristic crescendo-decrescendo breathing pattern that bed partners may describe as rhythmic stopping and starting.

Opioid-induced central apneas represent another major category. Chronic opioid therapy at morphine-equivalent doses of 200 mg/day or higher produces CSA in approximately 30% of patients, per a systematic review in the journal CHEST [9]. The mechanism involves direct depression of medullary chemoreceptors and blunting of the hypercapnic ventilatory response.

High-altitude periodic breathing, idiopathic CSA, and treatment-emergent CSA (appearing after CPAP initiation for OSA) round out the less common subtypes. Any patient presenting with apnea symptoms and a history of congestive heart failure, stroke, chronic opioid use, or recent travel above 2,500 meters warrants specific evaluation for central apneas rather than the default assumption of obstruction.

Overlap Syndrome and Complex Sleep Apnea

Some patients have both obstructive and central events on the same study. Complex sleep apnea syndrome (CompSAS), also called treatment-emergent CSA, appears in 5-15% of patients started on CPAP for OSA. The obstructive events resolve with pressure, but central apneas emerge or persist, suggesting an underlying instability in ventilatory control that the obstruction was masking.

The overlap syndrome, where OSA coexists with chronic obstructive pulmonary disease (COPD), affects an estimated 1-3.6% of the general population and carries compounded risk. A 2010 analysis published in the American Journal of Respiratory and Critical Care Medicine found that patients with untreated overlap syndrome had a 5-year mortality rate of 42.2% compared to 26.4% for COPD alone and 10.2% for OSA alone [10]. Nocturnal oxygen desaturation is characteristically more severe in overlap patients because their baseline PaO2 is already reduced from the underlying lung disease.

Identifying the correct phenotype matters for treatment selection. Pure OSA responds to CPAP. CompSAS may require adaptive servo-ventilation (ASV), though ASV is contraindicated in HFrEF with ejection fraction at or below 45% after the SERVE-HF trial showed increased cardiovascular mortality in that population [8].

How Sleep Apnea Is Diagnosed

Diagnosis begins with clinical suspicion. The STOP-BANG questionnaire scores eight binary items (Snoring, Tiredness, Observed apneas, high blood Pressure, BMI >35, Age >50, Neck circumference >40 cm, male Gender) and classifies patients as low (0-2), intermediate (3-4), or high (5-8) risk. A score of 5 or higher has a sensitivity of 83.6% for detecting moderate-to-severe OSA, according to a validation study of 11,875 surgical patients published in the British Journal of Anaesthesia [11].

The gold standard diagnostic test remains in-laboratory polysomnography (PSG), which simultaneously records EEG, electrooculography, submental EMG, airflow via nasal pressure transducer and thermistor, thoracic and abdominal respiratory effort, pulse oximetry, ECG, body position, and leg EMG. The American Academy of Sleep Medicine's 2017 clinical practice guideline specifies that level 1 PSG is required whenever central sleep apnea, hypoventilation syndromes, or complex comorbidities are suspected [12].

Home sleep apnea testing (HSAT) using type III or type IV portable monitors is appropriate for patients with a high pretest probability of moderate-to-severe OSA who lack significant comorbidities. HSAT typically measures airflow, respiratory effort, and oxygen saturation without EEG. The absence of EEG means HSAT may underestimate AHI because it cannot detect arousals, and a negative HSAT in a symptomatic patient should prompt in-lab PSG rather than diagnostic closure.

The 2020 Endocrine Society's guideline on testosterone therapy recommends screening for OSA before initiating testosterone replacement, given that exogenous testosterone may worsen sleep-disordered breathing through fluid redistribution and altered ventilatory drive [13].

Treatment Pathways by Type and Severity

Treatment selection follows a hierarchy determined by apnea type, severity, and patient anatomy.

CPAP remains first-line for moderate-to-severe OSA (AHI ≥ 15). The landmark SAVE trial (N=2,717), published in the New England Journal of Medicine, showed that CPAP reduced daytime sleepiness (Epworth Sleepiness Scale improvement of 2.5 points versus placebo) and improved quality of life in patients with cardiovascular disease and OSA, although it did not significantly reduce secondary cardiovascular endpoints at a mean adherence of 3.3 hours per night [14]. Adherence is the critical variable. The minimum effective threshold is widely cited as 4 hours per night on 70% of nights, but dose-response data suggest that 6+ hours produces superior neurocognitive and blood pressure outcomes.

Oral appliance therapy (mandibular advancement devices) is indicated for mild-to-moderate OSA or for patients who cannot tolerate CPAP. A Cochrane systematic review of 51 trials found that mandibular advancement devices reduced AHI by an average of 13.6 events per hour, though CPAP was more effective in head-to-head comparisons [15].

As the AASM's practice parameters state: "Oral appliances are recommended for patients with mild to moderate OSA who prefer them to CPAP, or who are intolerant of CPAP, or who fail treatment attempts with CPAP" [16].

Surgical options include uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (Inspire). The STAR trial for hypoglossal nerve stimulation (N=126) demonstrated a 68% reduction in median AHI at 12 months, from 29.3 to 9.0 events per hour, in select patients with moderate-to-severe OSA who had failed CPAP and had no concentric collapse at the velopharynx on drug-induced sleep endoscopy [17].

Weight loss is the only intervention with the potential to cure OSA rather than manage it. The Swedish Obese Subjects (SOS) study demonstrated that bariatric surgery reduced OSA prevalence from 74% to 44% at 2-year follow-up, though some degree of residual disease persisted in most patients [18].

Positional therapy (keeping patients off the supine position) is effective in the subset with positional OSA, defined as an AHI that is at least twice as high in the supine position as in non-supine positions. This phenotype accounts for roughly 50-60% of mild-to-moderate OSA cases.

When Sleep Apnea Symptoms Signal Something Else Entirely

Not every person who snores and wakes tired has sleep apnea. The differential diagnosis for this symptom cluster includes upper airway resistance syndrome (UARS), which produces arousals from increased respiratory effort without meeting AHI thresholds. Sleep-related hypoventilation from obesity, neuromuscular disease, or chest wall restriction can mimic OSA symptoms while requiring distinct treatment (bilevel ventilation or volume-targeted modes rather than CPAP).

Narcolepsy type 2 can present with excessive daytime sleepiness in the absence of cataplexy and may coexist with OSA. Hypothyroidism produces fatigue, weight gain, and upper airway soft tissue edema that can either mimic or directly cause OSA. Thyroid function testing (TSH, free T4) belongs in the workup of any patient with new-onset sleep apnea symptoms.

Nocturnal gastroesophageal reflux, periodic limb movement disorder, and chronic insomnia disorder each overlap with specific sleep apnea symptoms. The correct approach is polysomnography, not empiric CPAP, when the clinical picture is ambiguous.

Hormonal Connections: Testosterone, Thyroid, and Growth Hormone

Hormonal axes intersect with sleep apnea in ways that matter for HealthRX's patient population. Testosterone replacement therapy (TRT) can worsen OSA severity through increased upper airway collapsibility and changes to central chemoreceptor sensitivity. A meta-analysis of 7 randomized controlled trials published in Sleep Medicine Reviews found a statistically significant worsening of oxygen desaturation index in men receiving testosterone versus placebo, though the clinical magnitude was modest [19].

Hypothyroidism causes OSA in 25-35% of cases through myxedematous infiltration of upper airway tissue, and thyroid hormone replacement can partially reverse this. Growth hormone excess in acromegaly produces macroglossia and pharyngeal soft tissue hypertrophy. The prevalence of OSA in untreated acromegaly ranges from 45% to 80% depending on the case series, per data compiled in the Journal of Clinical Endocrinology & Metabolism [20].

Menopause also shifts the risk profile. The Wisconsin Sleep Cohort found that postmenopausal women not using hormone replacement therapy had an OSA prevalence 3.5 times higher than premenopausal women after adjusting for age and BMI [2]. Progesterone acts as a respiratory stimulant, and its decline during the menopausal transition likely contributes to this increase.

The Cardiovascular Toll of Untreated Disease

Untreated severe OSA (AHI ≥ 30) is an independent risk factor for hypertension, atrial fibrillation, stroke, and heart failure. The Sleep Heart Health Study found that men aged 40-70 with severe OSA had a 2.38-fold increased risk of incident heart failure compared to those without sleep-disordered breathing, after adjusting for known confounders [21]. Intermittent hypoxemia activates sympathetic tone, promotes systemic inflammation (elevated CRP, IL-6, TNF-alpha), and accelerates endothelial dysfunction through oxidative stress.

Resistant hypertension (blood pressure uncontrolled on 3+ agents including a diuretic) should always trigger sleep apnea screening. The American Heart Association estimates that 30-50% of patients with resistant hypertension have undiagnosed OSA [22]. Treating OSA with CPAP lowers 24-hour mean arterial pressure by 2-3 mmHg on average, with greater reductions in the resistant hypertension subgroup and in patients who use CPAP for more than 4 hours nightly.

Atrial fibrillation recurrence after cardioversion or ablation is 25% more likely in patients with untreated OSA, per a meta-analysis in the Journal of the American College of Cardiology [23]. CPAP adherence reduces this recurrence risk to a level comparable to patients without OSA, making sleep apnea treatment a prerequisite for optimal arrhythmia management.